Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 May;95(5):448-53.
doi: 10.1111/j.1349-7006.2004.tb03230.x.

Isoliquiritigenin, a flavonoid from licorice, reduces prostaglandin E2 and nitric oxide, causes apoptosis, and suppresses aberrant crypt foci development

Tetsuyuki Takahashi  1 , Nobuo Takasuka, Masaaki Iigo, Masaki Baba, Hoyoku Nishino, Hiroyuki Tsuda, Toru Okuyama
Affiliations

Isoliquiritigenin, a flavonoid from licorice, reduces prostaglandin E2 and nitric oxide, causes apoptosis, and suppresses aberrant crypt foci development

Tetsuyuki Takahashi et al. Cancer Sci. 2004 May.

Abstract

Isoliquiritigenin (ILTG), a flavonoid group compound, exists in some foodstuffs and herbal medicines such as licorice (Glycyrrhiza uralensis Fisher). Previously, we showed that ILTG can suppress azoxymethane (AOM)-induced colon carcinogenesis in ddY mice. In the present report, we present evidence that ILTG markedly decreases both prostaglandin E2 (PGE2) and nitric oxide (NO) production in RAW264.7 mouse macrophage cells. The decrease of PGE2 was dependent on cyclooxygenase-2 (COX-2) expression and the decrease of NO appeared due to a decrease in inducible nitric oxide synthase (iNOS) protein expression. In mouse and human colon carcinoma cells, ILTG treatment suppressed cell growth and caused apoptosis. Furthermore, in vivo administration of ILTG inhibited the induction of preneoplastic aberrant crypt foci (ACF) in the male F344 rat colon. Our results suggest that ILTG is a promising chemopreventive agent against colon carcinogenesis.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Yu SM, Kuo SC. Vasorelaxant effect of isoliquiritigenin, a novel soluble guanylate cyclase activator, in rat aorta. Br J Pharmacol 1995; 114: 1587–94. - PMC - PubMed
    1. Tawata M, Aida K, Noguchi T, Ozaki Y, Kume S, Sasaki H, Chin M, Onaya T. Anti‐platelet action of isoliquiritigenin, an aldose reductase inhibitor in licorice. Eur J Pharmacol 1992; 212: 87–92. - PubMed
    1. Kakegawa H, Matsumoto H, Satoh T. Inhibitory effect of some natural products on the activation of hyaluronidase and their anti‐allergic actions. Chem Pharm Bull 1992; 40: 1439–42. - PubMed
    1. Yamamoto S, Aizu E, Jiang H, Nakadate T, Kiyoto I, Wang JC, Kato R. The potent anti‐tumor promoting agent isoliquiritigenin. Carcinogenesis 1991; 2: 317–23. - PubMed
    1. Iwata S, Nishino T, Nagata N, Satomi Y, Nishino H, Shibata S. Antitumorigenic activities of chalcones. I. Inhibitory effects of chalcone derivatives on 32Pi incorporation into phospholipids of HeLa cells promoted by 12‐O‐tetradecanoyl‐phorbol 13‐acetate (TPA). Biol Pharm Bull 1995; 18: 1710–3. - PubMed

Publication types

MeSH terms